Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Levocarnitine for the Treatment of Polymorbid Patients

https://doi.org/10.20996/1819-6446-2020-02-11

Full Text:

Abstract

Effective and safe treatment of patients with polymorbidity is an urgent task of modern healthcare. Of particular difficulty is the treatment of patients with cardiovascular comorbidity, which requires an integrated approach to the treatment and development of a special, so-called patient-oriented approach. Modern scientific evidence proposes the use of levocarnitine, as part of complex therapy to increase its effectiveness. So, it was shown that levocarnitine can have a beneficial effect on blood pressure in patients with hypertension, especially those who are overweight and obese. Levocarnitine is also effective in the treatment of heart failure, which has been studied in several clinical studies, which demonstrated its ability to increase the ejection fraction of the left ventricle, stroke volume of blood and other indicators. Optimization of the bioavailability of nitrogen oxide (NO) and a decrease in systemic oxidative stress while taking levocarnitine plays an important positive role in complex therapy in patients with coronary artery disease: exertional angina and post-infarction cardiosclerosis, reducing the number of anginal attacks. Since levocarnitine has powerful antioxidant effects, it also has the neuroprotective effect found in in vitro studies in animal experiments. In case of impaired renal function, due to accelerated elimination and impaired reabsorption, a deficiency of levocarnitine in the body tissues develops, and therefore the US Food and Drug Administration (US FDA) decided on the possibility of using levocarnitine in patients on hemodialysis. Thus, taking into account the positive effects of levocarnitine in a number of frequently combined diseases, it can be considered as the drug of choice in the treatment of patients with polymorbidity.

About the Authors

A. P. Pereverzev
Russian Medical Academy of Continuous Professional Education
Russian Federation

Anton Р. Pereverzev – MD, PhD, Associate Professor, Chair of Therapy and Polymorbid Pathology

Barrikadnaya ul. 2/1, Moscow, 125993



D. A. Shevchenko
Pirogov Russian National Research Medical University
Russian Federation

Daniella A. Shevchenko – Postgraduate Student, Chair of Public Health and Health Care, Health Economics

Ostrovitianova ul. 1, Moscow, 117997



A. V. Filippova
Peoples’ Friendship University of Russia (RUDN University)
Russian Federation

Anastasia V. Filippova – Student

Miklukho-Maklaya ul. 6, Moscow, 117198



A. A. Kirichenko
Russian Medical Academy of Continuous Professional Education
Russian Federation

Andrey A. Kirichenko – MD, PhD, Professor, Chair of Therapy and Polymorbid Pathology

Barrikadnaya ul. 2/1, Moscow, 125993



I. F. Krotkova
Russian Medical Academy of Continuous Professional Education
Russian Federation

Irina F. Krotkova – MD, PhD, Associate Professor, Chair of Therapy and Polymorbid Pathology

Barrikadnaya ul. 2/1, Moscow, 125993



O. D. Ostroumova
Russian Medical Academy of Continuous Professional Education
Russian Federation

Olga D. Ostroumova – MD, PhD, Professor, Head of Chair of Therapy and Polymorbid Pathology

Barrikadnaya ul. 2/1, Moscow, 125993



References

1. Oganov R.G., Simanenkov V.I., Bakulin I.G., et al. Comorbidities in clinical practice. Algorithms for diagnostics and treatment. Cardiovascular Therapy and Prevention. 2019;18(1):5-66 (In Russ.) DOI:10.15829/1728-8800-2019-1-5-66.

2. Survey of Health, Ageing and Retirement in Europe (SHARE). Munich: Munich Center for the Economics of Aging; 2013. [cited by Jul 27, 2019]. Available from: http://www.share-project.org/home0/wave-4.html.

3. Barnett K., Mercer S.W., Norbury M., et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380(9836):37-43. DOI:10.1016/S0140-6736(12)60240-2.

4. Guiding principles for the care of older adults with multimorbidity: an approach for clinicians: American geriatrics society expert panel on the care of older adults with multimorbidity. J Am Geriatr Soc. 2012 Oct;60(10):E1-E25. DOI:10.1111/j.1532-5415.2012.04188.x.

5. Nizov A.A., Suchkova E.I., Dashkevich O.V., Trunina T.P. Cardiovascular comorbidity in the actual clinical practice of an outpatient physician. Comparative register study in the Ryazan region. Cardiovascular Therapy and Prevention. 2019;18 (2):70-5 (In Russ.) DOI:10.15829/1728-8800-2019-2-70-75.

6. DuGoff E.H., Canudas-Romo V., Buttorff C., et al. Multiple chronic conditions and life expectancy: a life table analysis. Med Care. 2014;52(8):688-94. DOI:10.1097/MLR.0000000000000166.

7. Vertkin A.L. Patient comorbidity. A guide for practitioners. Moscow: Eksmo; 2015 (In Russ.)

8. Yakhno N.N., Zakharov V.V., Lokshina A.B. Dementia. A guide for doctors. Third edition. Moscow: MEDpress-inform; 2011 (In Russ.)

9. Tkacheva O.N., Cherdak M.A., Mkhitaryan E.A. Acetylsalicylic acid in the prevention of ischemic stroke: ways to increase efficiency and safety. Russian MedicalJournal. 2017;(25):1880-3. (In Russ.)

10. Go A.S., Chertow G.M., Fan D., et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296-305. DOI:10.1056/NEJMoa041031

11. Afsar B., Turkmen K., Covic A., Kanbay M. An update on coronary artery disease and chronic kidney disease. Int J Nephrol. 2014;2014:767424. DOI:10.1155/2014/767424.

12. Tonelli M., Wiebe N., Culleton B., et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol. 2006;17(7):2034-47. DOI:10.1681/ASN.2005101085.

13. Sizova Z.M., Shikh E.V., Makhova A.A. The use of L-carnitine in general medical practice. Ter Arkhiv. 2019;91(1):114-20 (In Russ.) DOI:10.26442/00403660.2019.01.000040.

14. Rebouche C.J. Carnitine. In: Shils M.E., Shike M., Ross A.C.., Caballero B, Cousins R.J., eds. Modern Nutrition in Health and Disease. 10th ed. Philadelphia: Lippincott, Williams & Wilkins; 2006: 537-44.

15. Rebouche C.J. Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. Ann NY Acad Sci. 2004;1033:30-41. DOI:10.1196/annals.1320.003.

16. De Grandis D., Minardi C. Acetyl-L-carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long-term, randomised, doubleblind, placebo-controlled study. Drugs RD. 2002;3(4):223-31. DOI:10.2165/00126839-200203040-00001.

17. Gross C.J., Henderson L.M., Savaiano D.A. Uptake of L-carnitine, D-carnitine and acetyl-L-carnitine by isolated guinea-pig enterocytes. Biochim Biophys Acta. 1986;886(3):425-33. DOI:10.1016/0167-4889(86)90178-3.

18. Costell M., O'Connor J.E., Grisolia S. Age-dependent decrease of carnitine content in muscle of mice and humans. Biochem Biophys Res Commun. 1989;161(3):1135-43. DOI:10.1016/0006291x(89)91360-0.

19. Duran M., Loof N.E., Ketting D., Dorland L. Secondary carnitine deficiency. J Clin Chem Clin Biochem. 1990;28(5):359-63.

20. Pons R., De Vivo D.C. Primary and secondary carnitine deficiency syndromes. J Child Neurol. 1995 Nov;10 Suppl 2:S8-24.

21. Hagen T.M., Ingersoll R.T., Wehr C.M., et al. Acetyl-L-carnitine fed to old rats partially restores mitochondrial function and ambulatory activity. Proc Natl Acad Sci USA. 1998;95(16):9562-6. DOI:10.1073/pnas.95.16.9562.

22. Pesce V., Fracasso F., Cassano P., et al. Acetyl-L-carnitine supplementation to old rats partially reverts the agerelated mitochondrial decay of soleus muscle by activating peroxisome proliferator-activated receptor gamma coactivator-1alpha-dependent mitochondrial biogenesis. Rejuvenation Res. 2010;13(2-3):148-51. DOI:10.1089/rej.2009.0955.

23. Gómez L.A., Heath S.H., Hagen T.M. Acetyl-L-carnitine supplementation reverses the age-related decline in carnitine palmitoyltransferase 1 (CPT1) activity in interfibrillar mitochondria without changing the l-carnitine content in the rat heart. Mech Ageing Dev. 2012;133(2-3):99-106. DOI:10.1016/j.mad.2012.01.007.

24. Hagen T.M., Liu J., Lykkesfeldt J., et al. Feeding acetyl-L-carnitine and lipoic acid to old rats significantly improves metabolic function while decreasing oxidative stress. Proc Natl Acad Sci USA. 2002;99(4):1870-5. DOI:10.1073/pnas.261708898.

25. Liu J., Head E., Gharib A.M., et al. Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-alpha -lipoic acid. Proc Natl Acad Sci USA. 2002;99(4):2356-61. DOI:10.1073/pnas.261709299.

26. Spasov A.A., Iezhitsa I.N., Kravchenko M.S., et al. Comparative evaluation of the effect of carnitine stereoisomers and racemate on rat cardioand hemodynamics in a carnitine-deficient diet. Bulletin of the Russian Academy of Medical Sciences. 2006;7:20-7 (In Russ.)

27. Spasov A.A., Iezhitsa I.N., Kravchenko M.S., et al. Changes in the myocardium, skeletal muscle and liver in rats under conditions of a carnitine-deficient diet and after administration of optical carnitine isomers. Morphology. 2006; 129 (3): 48-51 (In Russ.)

28. Spasov A.A., Iezhitsa I.N., Kravchenko M.S., et al. Influence of L-, Dand DL-carnitine on morphometric parameters of skeletal muscles and physical performance of laboratory animals in conditions of carnitine-deficient diet. Bulletin of Experimental Biology and Medicine. 2006;14 (10):441-3 (In Russ.)

29. Lango R., Smolenski R.T.., Narkiewicz M, et al. Influence of L-carnitine and its derivatives on myocardial metabolism and function in ischemic heart disease and during cardiopulmonary bypass. Cardiovasc Res. 2001 Jul;51(1):21-9. DOI:10.1016/s0008-6363(01)00313-3.

30. Engel A.G.., Angelini C. Carnitine deficiency of human skeletal muscle with associated lipid storage myopathy: a new syndrome. Science 1973;179:899-902. DOI:10.1126/science.179.4076.899.

31. Ferrari R., Di Mauro S., Sherwood G., et al. L-Carnitine and its role in medicine. From function to therapy. New York: Academic Press; 1992.

32. Cipolla M.J., Nicoloff A., Rebello T., et al. Propionyl-L-carnitine dilates human subcutaneous arteries through an endothelium-dependent mechanism. J Vasc Surg. 1999;29(6):1097-103. DOI:10.1016/s0741-5214(99)70251-x.

33. Astashkin E.I., Glezer M.G., Orekhova N.S., et al. Influence of L-carnitine on reactive oxygen species production by blood phagocytes in postinfarction cardiosclerosis patients. Cardiovascular Therapy and Prevention. 2016;15(5):28-32 (In Russ.)

34. Askarpour M., Hadi A., Dehghani Kari Bozorg A., et al. Effects of L-carnitine supplementation on blood pressure: a systematic review and meta-analysis of randomized controlled trials. J Hum Hypertens. 2019;33:725-34. DOI:10.1038/s41371-019-0248-1.

35. Ruggenenti P., Cattaneo D., Loriga G., et al. Ameliorating Hypertension and Insulin Resistance in Subjects at Increased Cardiovascular Risk Effects of Acetyl-L-Carnitine Therapy. Hypertension. 2009;54:567-74. DOI:10.1161/HYPERTENSIONAHA.109.132522.

36. Xu Y., Jiang W., Chen G., et al. L-carnitine treatment of insulin resistance: A systematic review and meta-analysis. Adv Clin Exp Med. 2017;26(2):333-338. DOI:10.17219/acem/61609.

37. Astashkin E.I., Glezer M.G. The effect of L-carnitine on oxidative stress in cardiovascular diseases. Medical Advice. 2016;10:94-100 (In Russ.)

38. Rizos I. Three year survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration. Am Heart J. 2000;139(2 Pt 3):120-3. DOI:10.1067/mhj.2000.103917.

39. Song X., Qu H., Yang Z., et al. Efficacy and Safety of L-Carnitine Treatment for Chronic Heart Failure: A Meta-Analysis of Randomized Controlled Trials. Biomed Res Int. 2017;2017:6274854. DOI:10.1155/2017/6274854.

40. Mozheiko M.E., Bushueva E.V., Potanina M.V., Ryabikhin E.A. Can the addition of the metabolic drug levocarnitine to optimal drug therapy improve treatment efficacy in elderly patients with coronary heart disease complicated by chronic heart failure and cardiogenic encephalopathy? Consilium Medicum. 2019;21(12):106-11 (In Russ.)

41. Cacciatore L., Cerio R., Ciarimboli M., et al. The therapeutic effect of Lcarnitine in patients with exercise-induced stable angina: a controlled study. Drugs ExpClin Res. 1991;17(4):225-35.

42. Cherchi A., Lai C., Angelino F., et al. Effects of L-carnitine on exercise tolerance in chronic stable angina: a multicenter, double-blind, randomized, placebo controlled crossover study. Int J Clin Pharmacol Ther Toxicol. 1985;23(10):569-72.

43. Iyer R.N., Khan A.A., Gupta A., et al. L-carnitine moderately improves the exercise tolerance in chronic stable angina. J Assoc Physicians India. 2000;48(11):1050-2.

44. Wei X.J., Han M., Wei G.C., Duan C.H. Prognostic value of cerebrospinal fluid free fatty acid levels in patients with acute ischemic stroke. Frontiers in Human Neuroscience. 2015;9:402. DOI:10.3389/fnhum.2015.00402.

45. Golovkin V., Zuev A., Privalova M., et al. Cognitive impairment and cardiorespiratory dysfunction in dyscirculatory encephalopathy with cardiocerebral syndrome. Vrach. 2018;29(4):51-3 (In Russ.) DOI:10.29296/25877305-2018-04-09.

46. Chichanovskaya L.V., Bakhareva O.N., Sorokina K.B. A study of the safety and efficacy of L-carnitine in patients in the early recovery period of ischemic stroke. Korsakov’s Journal of Neurology and Psychiatry. 2017;12(2): (In Russ.) DOI:10.17116/jnevro201711712265-69.

47. Tsuji A. Functional relevance of carnitine transporter OCTN2 to brain distribution of L carnitine and acetyl-L-carnitine across the blood-brain barrier. J Neurochem. 2001;79:959-69. DOI:10.1046/j.1471-4159.2001.00621.x.

48. Taglialatela G., Caprioli A., Giuliani A., et al. Spatial memory and NGF levels in aged rats: natural variability and effects of acetyl-L-carnitine treatment. Exp Gerontol. 1996;31(5):577-87. DOI:10.1016/0531-5565(96)00052-6.

49. Angelucci L., Ramacci M.T., Taglialatela G., et al. Nerve growth factor binding in aged rat central nervous system: effect of acetyl-L-carnitine. J Neurosci Res. 1988;20:491-6. DOI:10.1002/jnr.490200413.

50. Piovesan P., Pacifici L., Taglialatela G., et al. Acetyl-L-carnitine treatment increases choline acetyltransferase activity and NGF levels in the CNS of adult rats following total fimbria-fornix transection. Brain Res. 1994;633:77-82. DOI:10.1016/0006-8993(94)91524-5.

51. Guarnieri G., Situlin R., Biolo G. Carnitine metabolism in uremia. Am J Kidney Dis. 2001;38(4 Suppl 1):63-7. DOI:10.1053/ajkd.2001.27408.

52. Hurot J.M., Cucherat M., Haugh M., Fouque D. Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review. J Am Soc Nephrol. 2002;13(3):708-14.

53. Kazmi W.H, Obrador G.T., Sternberg M., et al. Carnitine therapy is associated with decreased hospital utilization among hemodialysis patients. Am J Nephrol. 2005;25(2):106-15. DOI:10.1159/000084853.

54. Weinhandl E.D., Rao M., Gilbertson D.T., et al. Protective effect of intravenous levocarnitine on subsequent-month hospitalization among prevalent hemodialysis patients, 1998 to 2003. Am J Kidney Dis. 2007;50(5):803-12. DOI:10.1053/j.ajkd.2007.07.017.

55. Clinical practice guidelines for nutrition in chronic renal failure. K/DOQI, National Kidney Foundation. Am J Kidney Diseases. 2000;35(6 Suppl 2):S1-140.

56. Eknoyan G., Latos D.L., Lindberg J. Practice recommendations for the use of L-carnitine in dialysisrelated carnitine disorder. National Kidney Foundation Carnitine Consensus Conference. Am J Kidney Dis. 2003;41(4):868-76. DOI:10.1016/s0272-6386(03)00110-0.

57. Schreiber B. Safety of oral carnitine in dialysis patients. Semin Dial. 2002;15(1):71-2. DOI:10.1046/j.1525-139x.2002.0020a.x.

58. Flanagan J.L., Simmons P.A., Vehige J., et al. Role of carnitine in disease. Nutr Metab (Lond). 2010;7:30. DOI:10.1186/1743-7075-7-30.

59. Tkacheva O.N., ed. General principles of pharmacotherapy in the elderly and senile. Guidelines. M.: Prometheus; 2019 (In Russ.)

60. Tkacheva O.N., Pereverzev A.P., Kotovskaya Y.V., et al. Optimization of drug prescribing in elderly and senile patients: can polypharmacy be defeated? Russian Medical Journal. 2017;25:1826-8 (In Russ.)

61. Sychev D.A., ed. Polypharmacy in clinical practice: problem and solutions. St. Petersburg: TsOP “Profession”; 2016 (In Russ.)

62. Makhova A.A., Shich E.V., Kukes V.G., et al. Electroanalysis of cytochrome P450 3A4 catalytic properties with nanostructured electrodes: the influence of vitamin B group on diclofenac metabolism. BioNanoScience. 2011;1(1-2):46-52.


For citation:


Pereverzev A.P., Shevchenko D.A., Filippova A.V., Kirichenko A.A., Krotkova I.F., Ostroumova O.D. Levocarnitine for the Treatment of Polymorbid Patients. Rational Pharmacotherapy in Cardiology. 2020;16(1):139-146. (In Russ.) https://doi.org/10.20996/1819-6446-2020-02-11

Views: 218


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)